<p><em>SciSparc 计划在交易完成后立即开始这些专利技术的商业化</em></p>
<p>以色列特拉维夫，2026 年 1 月 13 日（全球新闻稿）-- SciSparc Ltd.（纳斯达克：SPRC）（“公司” 或 “SciSparc”），一家通过其控股子公司 NeuroThera Labs Inc.从事临床阶段制药开发的公司，今天宣布签署了一项最终协议，以收购来自 Xylo Technologies Ltd.（“Xylo”）的创新内窥镜系统和医疗相机的专利、商标和知识产权库。</p>
<p>MUSE™系统是一种一次性使用的创新内窥镜设备，旨在进行经口胃底折叠术，这是一种治疗胃食管反流病（“GERD”）的微创手术。</p>
<p>SciSparc 计划在交易完成后立即开始这些专利技术的商业化，基于已建立的基础，推动快速市场渗透和收入生成。</p>
<p>在 2019 年与一家位于上海的医疗器械公司通过许可和分销协议成功实现了 Xylo 在大中华区的商业化，Xylo 获得了 300 万美元的预付款，SciSparc 希望在北美、欧洲和拉丁美洲等高增长地区复制这一经过验证的模式，通过与领先的区域分销商追求类似的独家合作伙伴关系，加速全球商业化并解锁可观的收入来源。</p>
<p>根据最终协议的条款，SciSparc 将从 Xylo 收购与 MUSE™系统主要相关的完整专利、商标、专有技术及相关知识产权组合。作为收购资产的对价，SciSparc 将在交易完成时（“完成”）向 Xylo 发行一批普通股，该批普通股在 2026 年 3 月 8 日的完成日期时将占 SciSparc 已发行和流通股本的 19.99%（“已发行股份”）。SciSparc 可以自行决定选择以已发行股份的全部或部分替代发行预先融资的购买普通股的权证。</p>
<p>该交易仍需满足惯例的完成条件，包括任何所需的监管批准。</p>
<p>根据 MarkNtel Advisors 于 2025 年 5 月发布的市场研究报告，全球 GERD 设备市场在 2024 年的估值约为 25 亿美元，预计到 2030 年将达到 30.3 亿美元，从 2025 年到 2030 年年均增长率（CAGR）为 3.24%。</p>
<p><em>本新闻稿不构成在美国出售证券的要约。此处提及的证券尚未根据美国 1933 年证券法（修订版）（“美国证券法”）注册，且在未注册或不适用的情况下不得在美国提供或出售。</em></p>
<p><strong>关于 SciSparc Ltd.（纳斯达克：SPRC）：</strong></p>
<p>该公司通过其控股子公司 NeuroThera Labs Inc.从事临床阶段的制药开发。SciSparc 的重点是创建和增强基于大麻素药物的技术和资产组合。在这一重点下，该公司与其控股子公司 NeuroThera Labs Inc.目前正在进行以下基于 THC 和/或非精神活性 CBD 的药物开发项目：用于治疗抽动秽语症的 SCI-110，用于治疗阿尔茨海默病和激动的 SCI-210，以及用于治疗自闭症谱系障碍和癫痫持续状态的 SCI-210。该公司通过 NeuroThera Labs Inc.还拥有一家专注于在 Amazon.com 市场上销售基于大麻种子油产品的子公司的控股权。</p>
<p><strong>前瞻性声明：</strong></p>
<p>本新闻稿包含根据 1995 年《私人证券诉讼改革法案》和其他联邦证券法的 “安全港” 条款所定义的前瞻性声明。例如，SciSparc 在讨论以下内容时使用前瞻性声明：预计收购一组专利、商标和知识产权，涉及创新的内窥镜系统和医疗相机，包括来自 Xylo 的 MUSE TM 系统；在交割时支付给 Xylo 的收购资产的对价；公司计划将 Xylo 的许可和分销模式从大中华区复制到其他地区，如北美、欧洲和拉丁美洲；公司计划与领先的区域分销商追求独家合作伙伴关系，以加速商业化并解锁可观的收入来源；交割日期，公司打算商业化这些专利技术及其时机，以及全球 GERD 设备市场的预期价值和增长。新闻稿中描述的知识产权资产的收购需满足惯常的交割条件，包括任何所需的监管批准。由于这些声明涉及未来事件，并基于 SciSparc 当前的预期，因此它们面临各种风险和不确定性，SciSparc 的实际结果、表现或成就可能与本新闻稿中描述或暗示的内容有重大差异。本新闻稿中包含或暗示的前瞻性声明还面临其他风险和不确定性，包括在 SciSparc 于 2025 年 4 月 24 日向美国证券交易委员会提交的 20-F 表年度报告中 “风险因素” 标题下讨论的风险，以及后续向美国证券交易委员会的提交文件。除非法律另有要求，SciSparc 不承担更新或修订任何前瞻性声明的意图或义务，这些声明仅在作出时有效，无论是由于新信息、未来事件或情况还是其他原因。</p>
<p>投资者联系：</p>
<p>IR@scisparc.com</p>
<p>电话：+972-3-6167055</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5EWTNOaU0zTXpVNE5EUTRJelV3TURFd01qVXlOUT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5EWTNOaU0zTXpVNE5EUTRJelV3TURFd01qVXlOUT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzM0MDJiMTUtMjY5MS00ODYyLTkyZjMtNTc5OWMzNjVlOTkwLTUwMDEwMjUyNS0yMDI2LTAxLTEzLWVu/tiny/SciSparc-Ltd.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzM0MDJiMTUtMjY5MS00ODYyLTkyZjMtNTc5OWMzNjVlOTkwLTUwMDEwMjUyNS0yMDI2LTAxLTEzLWVu/tiny/SciSparc-Ltd.png"/></p>

SPRC

<p>SciSparc Ltd. 已签署一项最终协议，收购 Xylo Technologies Ltd. 的一系列专利和知识产权，涉及创新的内窥镜系统，包括 MUSE™ 系统。该公司计划在交易于 2026 年 3 月 8 日完成后立即商业化这些技术。SciSparc 旨在在北美、欧洲和拉丁美洲复制 Xylo 在大中华区成功的商业化模式，目标是不断增长的胃食管反流病（GERD）设备市场，预计到 2030 年将达到 30.3 亿美元</p>

<p><em>SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing</em></p>
<div class="lb-trans"><p><em>SciSparc 计划在交易完成后立即开始这些专利技术的商业化</em></p>
</div><p>TEL AVIV, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today the signing of a definitive agreement to acquire a treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. (&#34;Xylo”).</p>
<div class="lb-trans"><p>以色列特拉维夫，2026 年 1 月 13 日（全球新闻稿）-- SciSparc Ltd.（纳斯达克：SPRC）（“公司” 或 “SciSparc”），一家通过其控股子公司 NeuroThera Labs Inc.从事临床阶段制药开发的公司，今天宣布签署了一项最终协议，以收购来自 Xylo Technologies Ltd.（“Xylo”）的创新内窥镜系统和医疗相机的专利、商标和知识产权库。</p>
</div><p>The MUSE™ system is a single-use, innovative endoscopic device designed for transoral fundoplication, a minimally invasive procedure to treat gastroesophageal reflux disease (“GERD”).</p>
<div class="lb-trans"><p>MUSE™系统是一种一次性使用的创新内窥镜设备，旨在进行经口胃底折叠术，这是一种治疗胃食管反流病（“GERD”）的微创手术。</p>
</div><p>SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing, building on the established foundation to drive rapid market penetration and revenue generation.</p>
<div class="lb-trans"><p>SciSparc 计划在交易完成后立即开始这些专利技术的商业化，基于已建立的基础，推动快速市场渗透和收入生成。</p>
</div><p>Building on Xylo's successful commercialization in Greater China through licensing and distribution agreement with a Shanghai-based medical instruments company in 2019, under which Xylo received $3 million up front, SciSparc seeks to replicate this proven model across high-growth territories, such as North America, Europe and Latin America, by pursuing similar exclusive partnerships with leading regional distributors to accelerate global commercialization and unlock substantial revenue streams.</p>
<div class="lb-trans"><p>在 2019 年与一家位于上海的医疗器械公司通过许可和分销协议成功实现了 Xylo 在大中华区的商业化，Xylo 获得了 300 万美元的预付款，SciSparc 希望在北美、欧洲和拉丁美洲等高增长地区复制这一经过验证的模式，通过与领先的区域分销商追求类似的独家合作伙伴关系，加速全球商业化并解锁可观的收入来源。</p>
</div><p>Under the terms of the definitive agreement, SciSparc will acquire the complete portfolio of patents, trademarks, know-how, and related intellectual property rights, mainly associated with the MUSE™ system, from Xylo. In consideration for the acquired assets, SciSparc will issue to Xylo, upon the closing of the transaction (the “Closing”), an amount of ordinary shares of the Company, which shall represent, as of the Closing date, which is set on March 8, 2026, 19.99% of the issued and outstanding share capital of SciSparc (the “Issued Shares”). SciSparc may elect, at its sole discretion, to issue, in lieu (in whole or in part) the Issued Shares, pre-funded warrants to purchase ordinary shares.</p>
<div class="lb-trans"><p>根据最终协议的条款，SciSparc 将从 Xylo 收购与 MUSE™系统主要相关的完整专利、商标、专有技术及相关知识产权组合。作为收购资产的对价，SciSparc 将在交易完成时（“完成”）向 Xylo 发行一批普通股，该批普通股在 2026 年 3 月 8 日的完成日期时将占 SciSparc 已发行和流通股本的 19.99%（“已发行股份”）。SciSparc 可以自行决定选择以已发行股份的全部或部分替代发行预先融资的购买普通股的权证。</p>
</div><p>The transaction remains subject to customary closing conditions, including any required regulatory approvals.</p>
<div class="lb-trans"><p>该交易仍需满足惯例的完成条件，包括任何所需的监管批准。</p>
</div><p>According to a May 2025 market research report by MarkNtel Advisors, the global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030.</p>
<div class="lb-trans"><p>根据 MarkNtel Advisors 于 2025 年 5 月发布的市场研究报告，全球 GERD 设备市场在 2024 年的估值约为 25 亿美元，预计到 2030 年将达到 30.3 亿美元，从 2025 年到 2030 年年均增长率（CAGR）为 3.24%。</p>
</div><p><em>This press release does not constitute an offer of securities for sale in the United States. The securities referred to herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and such securities may not be offered or sold within the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act.</em></p>
<div class="lb-trans"><p><em>本新闻稿不构成在美国出售证券的要约。此处提及的证券尚未根据美国 1933 年证券法（修订版）（“美国证券法”）注册，且在未注册或不适用的情况下不得在美国提供或出售。</em></p>
</div><p><strong>About SciSparc Ltd. (Nasdaq: SPRC):</strong></p>
<div class="lb-trans"><p><strong>关于 SciSparc Ltd.（纳斯达克：SPRC）：</strong></p>
</div><p>The Company, through its majority-owned subsidiary NeuroThera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera Labs Inc., are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through NeuroThera Labs Inc., also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.</p>
<div class="lb-trans"><p>该公司通过其控股子公司 NeuroThera Labs Inc.从事临床阶段的制药开发。SciSparc 的重点是创建和增强基于大麻素药物的技术和资产组合。在这一重点下，该公司与其控股子公司 NeuroThera Labs Inc.目前正在进行以下基于 THC 和/或非精神活性 CBD 的药物开发项目：用于治疗抽动秽语症的 SCI-110，用于治疗阿尔茨海默病和激动的 SCI-210，以及用于治疗自闭症谱系障碍和癫痫持续状态的 SCI-210。该公司通过 NeuroThera Labs Inc.还拥有一家专注于在 Amazon.com 市场上销售基于大麻种子油产品的子公司的控股权。</p>
</div><p><strong>Forward-Looking Statements:</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明：</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of the &#34;safe harbor&#34; provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses: the expected acquisition of a portfolio of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE TM system from Xylo; the consideration for the acquired assets to be paid to Xylo at Closing; the Company’s plans to replicate Xylo’s licensing and distribution model from Greater China to other territories, such as North America, Europe and Latin America; the Company’s plans to pursue exclusive partnerships with leading regional distributors to accelerate commercialization and unlock substantial revenue streams; the Closing Date, the Company’s intention to commercialize these patented technologies and the timing thereof and the expected value and growth of the global GERD device market. The acquisition of the intellectual property assets described in this press release is subject to customary closing conditions, including any required regulatory approvals. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading &#34;Risk Factors&#34; in SciSparc's Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1995 年《私人证券诉讼改革法案》和其他联邦证券法的 “安全港” 条款所定义的前瞻性声明。例如，SciSparc 在讨论以下内容时使用前瞻性声明：预计收购一组专利、商标和知识产权，涉及创新的内窥镜系统和医疗相机，包括来自 Xylo 的 MUSE TM 系统；在交割时支付给 Xylo 的收购资产的对价；公司计划将 Xylo 的许可和分销模式从大中华区复制到其他地区，如北美、欧洲和拉丁美洲；公司计划与领先的区域分销商追求独家合作伙伴关系，以加速商业化并解锁可观的收入来源；交割日期，公司打算商业化这些专利技术及其时机，以及全球 GERD 设备市场的预期价值和增长。新闻稿中描述的知识产权资产的收购需满足惯常的交割条件，包括任何所需的监管批准。由于这些声明涉及未来事件，并基于 SciSparc 当前的预期，因此它们面临各种风险和不确定性，SciSparc 的实际结果、表现或成就可能与本新闻稿中描述或暗示的内容有重大差异。本新闻稿中包含或暗示的前瞻性声明还面临其他风险和不确定性，包括在 SciSparc 于 2025 年 4 月 24 日向美国证券交易委员会提交的 20-F 表年度报告中 “风险因素” 标题下讨论的风险，以及后续向美国证券交易委员会的提交文件。除非法律另有要求，SciSparc 不承担更新或修订任何前瞻性声明的意图或义务，这些声明仅在作出时有效，无论是由于新信息、未来事件或情况还是其他原因。</p>
</div><p>Investor Contact:</p>
<div class="lb-trans"><p>投资者联系：</p>
</div><p>IR@scisparc.com</p>
<div class="lb-trans"><p>IR@scisparc.com</p>
</div><p>Tel: +972-3-6167055</p>
<div class="lb-trans"><p>电话：+972-3-6167055</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5EWTNOaU0zTXpVNE5EUTRJelV3TURFd01qVXlOUT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyNDY3NiM3MzU4NDQ4IzUwMDEwMjUyNQ=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzM0MDJiMTUtMjY5MS00ODYyLTkyZjMtNTc5OWMzNjVlOTkwLTUwMDEwMjUyNS0yMDI2LTAxLTEzLWVu/tiny/SciSparc-Ltd.png" alt="" original-src="https://ml.globenewswire.com/media/MzM0MDJiMTUtMjY5MS00ODYyLTkyZjMtNTc5OWMzNjVlOTkwLTUwMDEwMjUyNS0yMDI2LTAxLTEzLWVu/tiny/SciSparc-Ltd.png"/></p>

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity | SPRC Stock News

SciSparc 签署最终协议，收购内窥镜市场的专利库，进军数十亿美元的市场机会 | SPRC 股票新闻